Brenda Sickle Santanello, MD
Surgical Oncology · Columbus, OHNPI 1548259492
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Stryker at 52.6% of the total. 2025 is the largest year on record at $1,346, 4.6 times the $295 reported in 2019.
Across 56 payments — averaging $41.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$1K
- Merck$385
- Vector Surgical, LLC$150
- Genentech USA, Inc.$93
- AstraZeneca$92
- Jazz Pharmaceuticals Inc.$83
- plus $312 from 12 others
What the payments were for
- Consulting fees$1506%
- Travel & lodging$97842%
- Food & beverage$1,18650%
- Education$372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 6 | $1,235 |
| Merck | 20 | $385 |
| Vector Surgical, LLC | 1 | $150 |
| Genentech USA, Inc. | 5 | $93 |
| AstraZeneca | 4 | $92 |
| Jazz Pharmaceuticals Inc. | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Amgen | 3 | $44 |
| Hologic Inc | 1 | $40 |
| Medtronic(2 entities) | 2 | $38 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| Gilead | 1 | $21 |
| Astellas Pharma US Inc | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $16 |
| Pharmaand GmbH | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- 1788$1,085
- MarginMarker$150
How this compares
$2,350 in reported general payments places this provider in the 65th percentile of 69 surgical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 111 | $2,105 |
| Tamoxifen Citrate | 35 | $985 |
| Alendronate Sodium | 51 | $587 |
| SynthroidLevothyroxine Sodium | 14 | $586 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $36 |
| Levothyroxine Sodium | 13 | $30 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Columbus
- Carl SchmidtColumbus$26K
- Mary DillhoffColumbus$15K
- Susan TsaiColumbus$8K
- Joal BeaneColumbus$8K
- Ramy Hany FouadColumbus$3K
- Bridget OppongColumbus$2K
- Carlo ContrerasColumbus$2K
- Sara MyersColumbus$2K
- Pamela LuColumbus$2K
- Jordan CloydColumbus$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.